News & Updates

Autoimmune disease ups risk of immune-related adverse events in melanoma

21 Aug 2021

Cutaneous melanoma patients with a pre-existing autoimmune disease (pAID) are at substantially greater risk of immune-related adverse events (irAEs), reveals a recent study.

Autoimmune disease ups risk of immune-related adverse events in melanoma

21 Aug 2021

Frequent energy drink consumption ups risk of asthma, allergic rhinitis, atopic dermatitis

14 Aug 2021

People who regularly consume energy drinks are at heightened risk of developing allergic diseases, including asthma, allergic rhinitis (AR), and atopic dermatitis (AD), according to a study in Korea.

Frequent energy drink consumption ups risk of asthma, allergic rhinitis, atopic dermatitis

14 Aug 2021

Patients with psoriasis, joint pain use more analgesics

07 Aug 2021

Patients with psoriasis also suffering from concomitant psoriatic arthritis more frequently use analgesics than the general population, an effect driven by joint pain, a new study has found.

Patients with psoriasis, joint pain use more analgesics

07 Aug 2021

Prolonged monitoring after propranolol use for infantile haemangioma does not predict adverse events

07 Aug 2021

Repeated vital sign monitoring for initiation and escalation of oral propranolol has seldomly led to a change in management of infantile haemangioma and is not predictive of future adverse events, results of a recent study have shown. Serious adverse events occurring during therapy are few, of which none are cardiovascular.

Prolonged monitoring after propranolol use for infantile haemangioma does not predict adverse events

07 Aug 2021

Psoriasis patients on biologics at risk of HBV, HCV reactivation

07 Aug 2021

Reactivations of hepatitis B (HBV) and C virus (HCV) are more likely among patients with psoriasis treated with biologic agents, especially those who are seropositive for hepatitis B surface antigen and hepatitis B e-antigen and undergoing tumour necrosis factor-α inhibitor therapy, reveals a recent study.

Psoriasis patients on biologics at risk of HBV, HCV reactivation

07 Aug 2021

Which systemic drug is safest for atopic dermatitis patients?

06 Aug 2021

Among systemic immunomodulatory drugs, cyclosporine and methotrexate demonstrate the lowest risks of serious infections at 6 months in adults with atopic dermatitis (AD), suggests a study. On the other hand, prednisone, azathioprine, and mycophenolate are associated with increased risks when compared with methotrexate.

Which systemic drug is safest for atopic dermatitis patients?

06 Aug 2021

Rituximab bests MMF for pemphigus vulgaris

06 Aug 2021 by

The humanized anti-CD20 monoclonal antibody rituximab was superior to mycophenolate mofetil (MMF) in terms of producing sustained complete remission* (CR) and a glucocorticoid-sparing effect in patients with moderate-to-severe pemphigus vulgaris, the PEMPHIX study has shown.

Rituximab bests MMF for pemphigus vulgaris

06 Aug 2021

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

05 Aug 2021 by

Both tetracycline treatment and clindamycin–rifampicin combination therapy demonstrate significant efficacy after 12 weeks in patients with hidradenitis suppurativa (HS), reports a study. Regardless of disease severity, efficacy does not substantially differ between the two treatments.

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

05 Aug 2021

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021 by

Treatment with ixekizumab (IXE) for moderate-to-severe plaque psoriasis is consistently safe and effective through 264 weeks in patients using the approved dose, according to the UNCOVER-3 study.

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

News & Updates

Filter by Specialty:

Specialty:

Autoimmune disease ups risk of immune-related adverse events in melanoma

Autoimmune disease ups risk of immune-related adverse events in melanoma

Frequent energy drink consumption ups risk of asthma, allergic rhinitis, atopic dermatitis

Frequent energy drink consumption ups risk of asthma, allergic rhinitis, atopic dermatitis

Patients with psoriasis, joint pain use more analgesics

Patients with psoriasis, joint pain use more analgesics

Prolonged monitoring after propranolol use for infantile haemangioma does not predict adverse events

Prolonged monitoring after propranolol use for infantile haemangioma does not predict adverse events

Psoriasis patients on biologics at risk of HBV, HCV reactivation

Psoriasis patients on biologics at risk of HBV, HCV reactivation

Which systemic drug is safest for atopic dermatitis patients?

Which systemic drug is safest for atopic dermatitis patients?

Rituximab bests MMF for pemphigus vulgaris

Rituximab bests MMF for pemphigus vulgaris

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

Tetracyline vs clindamycin–rifampicin: which is more effective for hidradenitis suppurativa?

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)